Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i in Heart Failure Patients With LVADs
NCT05278962Phase 4Completed
- Sponsor
- University of Chicago
- Start
- Sep 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by University of Chicago. Primary endpoint: Change in Left Ventricular End-diastolic Dimension at 6 months. Started Sep 2022; status: completed.
02
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05278962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278962.